Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study

Background and objectives: It was postulated that in patients with membranous nephropathy (MN), four weekly doses of Rituximab (RTX) would result in more effective B cell depletion, a higher remission rate, and maintaining the same safety profile compared with patients treated with RTX dosed at 1 g...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Fervenza, Fernando C., Abraham, Roshini S., Erickson, Stephen B., Irazabal, Maria Valentina, Eirin, Alfonso, Specks, Ulrich, Nachman, Patrick H., Bergstralh, Eric J., Leung, Nelson, Cosio, Fernando G., Hogan, Marie C., Dillon, John J., Hickson, LaTonya J., Li, Xujian, Cattran, Daniel C.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Nephrology 2010
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2994079/
https://ncbi.nlm.nih.gov/pubmed/20705965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.05080610
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares